Delivery Order SPE2DB22D2006-SPE2DB26FV5WY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,840.13 to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's ability...
- The Defense Logistics Agency awarded a $7,527.37 delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count units) with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical federal healthcare vendor that...
- The Defense Logistics Agency awarded a $3,818.49 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the agency. The product will be performed at the vendor's Conshohocken, Pennsylvania...
- The Defense Logistics Agency awarded a delivery order valued at $1,911.13 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) with an ultimate completion date of June 2, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award status. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $28,026.72 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed price delivery order was issued on August 12, 2025, with an ultimate completion date of August 13, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order valued at $19,783.48 to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units). The contract is a firm fixed-price delivery order with a completion date of June 26, 2025, and is being performed at the contractor's location in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded through the federal procurement process. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $2,852.76 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30 tablets) on May 28, 2025, with completion scheduled for May 29, 2025. The contract utilizes firm fixed pricing and is classified as a non-set-aside award, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,877.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a standard pharmaceutical supply transaction under the company's broader relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,618.40 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This is a firm fixed price, non-set-aside contract with a completion date of September 30, 2025, and was awarded on September 29, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count package) on July 29, 2025, with completion targeted for July 30, 2025. This competitive award—utilizing firm fixed pricing with no set-aside designation—represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB26FV5WYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,203.92 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in a 30-count package. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 29, 2025, and was awarded on October 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/28/25 |